Mesenchymal Migration as a Therapeutic Target in Glioblastoma
暂无分享,去创建一个
G. O'Neill | S. Kellie | Jessie Zhong | Andre Paul | Stewart J. Kellie | Geraldine M. O'Neill | A. Paul | J. Zhong | Jessie Zhong
[1] S. Dedhar,et al. αv integrins regulate cell proliferation through integrin-linked kinase (ILK) in ovarian cancer cells , 2003, Oncogene.
[2] Fan Wang,et al. Integrin αvβ3-Targeted Radioimmunotherapy of Glioblastoma Multiforme , 2008, Clinical Cancer Research.
[3] Keith Burridge,et al. Recruitment of the Arp2/3 complex to vinculin , 2002, The Journal of cell biology.
[4] D. Cheresh,et al. Definition of two angiogenic pathways by distinct alpha v integrins. , 1995, Science.
[5] K. Vuori,et al. CAS/Crk Coupling Serves as a “Molecular Switch” for Induction of Cell Migration , 1998, The Journal of cell biology.
[6] X. Bu,et al. EFFECT OF THE ANGIOGENESIS INHIBITOR CILENGITIDE (EMD 121974) ON GLIOBLASTOMA GROWTH IN NUDE MICE , 2006, Neurosurgery.
[7] D. Nelson,et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. , 1993, International journal of radiation oncology, biology, physics.
[8] D. Cheresh,et al. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. , 1991, The Journal of clinical investigation.
[9] K. Schlingensiepen,et al. Effects of Transforming Growth Factor‐β1 on Collagen Synthesis, Integrin Expression, Adhesion an Invasion of Glioma Cells , 1995 .
[10] M. Mrugala,et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. , 2009, Neurology.
[11] W. F. Hillier. Total Left Cerebral Hemispherectomy for Malignant Glioma , 1954, Neurology.
[12] Kristiina Vuori,et al. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures , 2007, Molecular Cancer Therapeutics.
[13] Andreas S. Beutler,et al. Diffuse brain invasion of glioma cells requires β1 integrins , 1996 .
[14] C. Bokemeyer,et al. Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway , 2008, Journal of experimental & clinical cancer research : CR.
[15] D. Price,et al. The motility of glioblastoma tumour cells is modulated by intracellular cofilin expression in a concentration-dependent manner. , 2005, Cell motility and the cytoskeleton.
[16] Xinming Cai,et al. Structural Basis for the Autoinhibition of Focal Adhesion Kinase , 2007, Cell.
[17] Michael J. Fry,et al. Phosphatidylinositol-3-OH kinase direct target of Ras , 1994, Nature.
[18] D. Kaplan,et al. SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. , 2004, Molecular cancer research : MCR.
[19] G. O'Neill,et al. Molecular basis for HEF1/NEDD9/Cas-L action as a multifunctional co-ordinator of invasion, apoptosis and cell cycle , 2007, Cell Biochemistry and Biophysics.
[20] J. Thiery. Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.
[21] Gabriel A Silva,et al. Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS , 2008, BMC Neuroscience.
[22] Osamu Ohmori,et al. A novel low‐molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth , 2007, Molecular carcinogenesis.
[23] D. Louis,et al. In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation. , 2005, The American journal of pathology.
[24] Timothy A. Springer,et al. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1) , 1987, Cell.
[25] A. Ridley. Rho GTPases and actin dynamics in membrane protrusions and vesicle trafficking. , 2006, Trends in cell biology.
[26] K. Kinzler,et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[27] K. Rottner,et al. Interplay between Rac and Rho in the control of substrate contact dynamics , 1999, Current Biology.
[28] A. Baron,et al. Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[29] V. Tse,et al. Recurrent glioblastoma multiforme: a review of natural history and management options. , 2006, Neurosurgical focus.
[30] B. Felding-Habermann,et al. Activation of tumor cell integrin αvβ3 controls angiogenesis and metastatic growth in the brain , 2009, Proceedings of the National Academy of Sciences.
[31] F. McCormick,et al. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. , 1997, Science.
[32] A. Puisieux,et al. Metastasis: a question of life or death , 2006, Nature Reviews Cancer.
[33] Peter J. Parker,et al. The activation of phosphatidylinositol 3-kinase by Ras , 1994, Current Biology.
[34] Jill M. Stukel,et al. Two-step synthesis of multivalent cancer-targeting constructs. , 2010, Biomacromolecules.
[35] P. Pellicena,et al. Src Phosphorylates Cas on Tyrosine 253 to Promote Migration of Transformed Cells* , 2003, Journal of Biological Chemistry.
[36] M. Wigler,et al. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.
[37] P. Kleihues,et al. Primary and secondary glioblastomas: from concept to clinical diagnosis. , 1999, Neuro-oncology.
[38] Nicole S. Bryce,et al. Specification of actin filament function and molecular composition by tropomyosin isoforms. , 2003, Molecular biology of the cell.
[39] Michael E. Berens,et al. Molecular Mechanisms of Glioma Cell Migration and Invasion , 2004, Journal of Neuro-Oncology.
[40] John Condeelis,et al. The cofilin pathway in breast cancer invasion and metastasis , 2007, Nature Reviews Cancer.
[41] P. Friedl,et al. Proteolytic and non-proteolytic migration of tumour cells and leucocytes. , 2003, Biochemical Society symposium.
[42] J. Groot,et al. Improving the prognosis for patients with glioblastoma: the rationale for targeting Src , 2009, Journal of Neuro-Oncology.
[43] M. Westphal,et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. , 2000, Neoplasia.
[44] Yi Zheng,et al. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[45] A. Donson,et al. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma , 2007, Pediatric blood & cancer.
[46] J. Parsons,et al. pp125FAK-dependent tyrosine phosphorylation of paxillin creates a high-affinity binding site for Crk , 1995, Molecular and cellular biology.
[47] J. Parsons,et al. Inhibition of cell spreading by expression of the C-terminal domain of focal adhesion kinase (FAK) is rescued by coexpression of Src or catalytically inactive FAK: a role for paxillin tyrosine phosphorylation , 1997, Molecular and cellular biology.
[48] Faith Davis,et al. Brain tumor survival: Results from the National Cancer Data Base , 1998, Journal of Neuro-Oncology.
[49] L. Shaw,et al. RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion , 2000, Oncogene.
[50] G. Semenza,et al. Molecular Events Implicated in Brain Tumor Angiogenesis and Invasion , 2000, Pediatric Neurosurgery.
[51] J. Schneider-Mergener,et al. Subsets of the Major Tyrosine Phosphorylation Sites in Crk-associated Substrate (CAS) Are Sufficient to Promote Cell Migration* , 2004, Journal of Biological Chemistry.
[52] T. Mikkelsen,et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] R. Mamillapalli,et al. Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases , 2000, Current Biology.
[54] Paul S Mischel,et al. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. , 2009, Cancer research.
[55] C. Beaudry,et al. Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis , 2003, Journal of Cell Science.
[56] David M Sabatini,et al. An expanding role for mTOR in cancer. , 2005, Trends in molecular medicine.
[57] Y. Yonekawa,et al. Amplification and Overexpression of MDM2 in Primary (de novo) Glioblastomas , 1997, Journal of neuropathology and experimental neurology.
[58] J. Condeelis,et al. Phospholipase C and cofilin are required for carcinoma cell directionality in response to EGF stimulation , 2004, The Journal of cell biology.
[59] Christopher Beadle,et al. The role of myosin II in glioma invasion of the brain. , 2008, Molecular biology of the cell.
[60] W. Pardridge. Drug Targeting to the Brain , 2007, Pharmaceutical Research.
[61] B. Vanhaesebroeck,et al. The PI3K-PDK1 connection: more than just a road to PKB. , 2000, The Biochemical journal.
[62] M. Westphal,et al. Glioma cell adhesion and migration on human brain sections. , 1998, Anticancer research.
[63] C. Turner,et al. Characterization of Tyrosine Phosphorylation of Paxillin in Vitro by Focal Adhesion Kinase (*) , 1995, The Journal of Biological Chemistry.
[64] Donna J. Webb,et al. FAK–Src signalling through paxillin, ERK and MLCK regulates adhesion disassembly , 2004, Nature Cell Biology.
[65] Jeremy Fairbank,et al. Historical Perspective , 1987, Do We Really Understand Quantum Mechanics?.
[66] M. Berens,et al. Molecular targets of glioma invasion , 2007, Cellular and Molecular Life Sciences.
[67] Pierre-Marie Martin,et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] Liz Y. Han,et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. , 2007, Cancer research.
[69] G. Alghisi,et al. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. , 2006, Endothelium : journal of endothelial cell research.
[70] Sábata S Constancio,et al. Crk-Associated Substrate Tyrosine Phosphorylation Sites Are Critical for Invasion and Metastasis of Src-Transformed Cells , 2005, Molecular Cancer Research.
[71] T. Hunter,et al. Evidence for in vivo phosphorylation of the Grb2 SH2-domain binding site on focal adhesion kinase by Src-family protein-tyrosine kinases , 1996, Molecular and cellular biology.
[72] Cramer Lp. Organization and polarity of actin filament networks in cells: implications for the mechanism of myosin-based cell motility. , 1999 .
[73] W. Cance,et al. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. , 1995, Cancer research.
[74] E. Golemis,et al. HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells , 2007, Oncogene.
[75] Y. Okada,et al. Membrane Type 1 Matrix Metalloproteinase Digests Interstitial Collagens and Other Extracellular Matrix Macromolecules* , 1997, The Journal of Biological Chemistry.
[76] M. Frame,et al. The catalytic activity of Src is dispensable for translocation to focal adhesions but controls the turnover of these structures during cell motility , 1998, The EMBO journal.
[77] Anastasia Khvorova,et al. Identification of genes that regulate epithelial cell migration using an siRNA screening approach , 2008, Nature Cell Biology.
[78] Horst Kessler,et al. N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists , 1999 .
[79] Erkki Ruoslahti,et al. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule , 1984, Nature.
[80] D. Lauffenburger,et al. Cell Migration: A Physically Integrated Molecular Process , 1996, Cell.
[81] P. Friedl,et al. Tumour-cell invasion and migration: diversity and escape mechanisms , 2003, Nature Reviews Cancer.
[82] T. MacDonald,et al. Pediatric High-grade Glioma: Molecular Genetic Clues for Innovative Therapeutic Approaches , 2005, Journal of Neuro-Oncology.
[83] K. Pantel,et al. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. , 1999, Cancer research.
[84] K. Stein,et al. Temozolomide for high grade glioma. , 2008, The Cochrane database of systematic reviews.
[85] W. Cai,et al. Integrin αvβ3 Antagonists for Anti-Angiogenic Cancer Treatment , 2007 .
[86] R. Kessin,et al. Dictyostelium: Cell Motility and the Cytoskeleton , 2001 .
[87] Christoph Ballestrem,et al. Vinculin controls focal adhesion formation by direct interactions with talin and actin , 2007, The Journal of cell biology.
[88] Shile Huang,et al. Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins , 2008, Oncogene.
[89] Jochen Herms,et al. Imaging glioma cell invasion in vivo reveals mechanisms of dissemination and peritumoral angiogenesis , 2009, Glia.
[90] Kenneth M. Yamada,et al. Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas. , 1999, Cancer research.
[91] T. Mikkelsen,et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme. , 2008, Expert opinion on investigational drugs.
[92] C. Bokemeyer,et al. TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis , 2010, Investigational New Drugs.
[93] Jyrki Heino,et al. Cellular receptors of extracellular matrix molecules. , 2009, Current pharmaceutical design.
[94] J. Olson,et al. Benefit of temozolomide compared to procarbazine in treatment of glioblastoma multiforme at first relapse: effect on neurological functioning, performance status, and health related quality of life. , 2005, Cancer investigation.
[95] D. Schlaepfer,et al. Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration. , 1999, Journal of cell science.
[96] D. Louis. The p53 Gene and Protein in Human Brain Tumors , 1994, Journal of neuropathology and experimental neurology.
[97] W. Vandertop,et al. Genetic profiling of a distant second glioblastoma multiforme after radiotherapy: Recurrence or second primary tumor? , 2006, Journal of neurosurgery.
[98] C. Gladson,et al. FAK signaling in anaplastic astrocytoma and glioblastoma tumors. , 2003, Cancer journal.
[99] R. Pazdur,et al. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[100] P. Friedl. Prespecification and plasticity: shifting mechanisms of cell migration. , 2004, Current opinion in cell biology.
[101] E. Sahai,et al. Rac Activation and Inactivation Control Plasticity of Tumor Cell Movement , 2008, Cell.
[102] Gareth E. Jones,et al. Focal adhesion kinase controls actin assembly via a FERM-mediated interaction with the Arp2/3 complex , 2007, Nature Cell Biology.
[103] K. Kaibuchi,et al. Rho-Kinase–Mediated Contraction of Isolated Stress Fibers , 2001, The Journal of cell biology.
[104] Alan Hall,et al. Rho GTPases Control Polarity, Protrusion, and Adhesion during Cell Movement , 1999, The Journal of cell biology.
[105] G. E. Jones,et al. Rho family proteins and cell migration. , 1999, Biochemical Society symposium.
[106] G. O'Neill,et al. Specialisation of the tropomyosin composition of actin filaments provides new potential targets for chemotherapy. , 2006, Current cancer drug targets.
[107] Tony Hunter,et al. Multiple Grb2-Mediated Integrin-Stimulated Signaling Pathways to ERK2/Mitogen-Activated Protein Kinase: Summation of Both c-Src- and Focal Adhesion Kinase-Initiated Tyrosine Phosphorylation Events , 1998, Molecular and Cellular Biology.
[108] A. Ridley. Rho GTPases and cell migration. , 2001, Journal of cell science.
[109] Victoria Sanz-Moreno,et al. Rho-GTPase signaling drives melanoma cell plasticity , 2009, Cell cycle.
[110] S. Itzkovitz,et al. Functional atlas of the integrin adhesome , 2007, Nature Cell Biology.
[111] J. Gunnersen,et al. Growth and migration markers of rat C6 glioma cells identified by serial analysis of gene expression , 2000, Glia.
[112] G. O'Neill,et al. Integrin signalling: a new Cas(t) of characters enters the stage. , 2000, Trends in cell biology.
[113] D. Zagzag,et al. Angiogenesis in Gliomas: Biology and Molecular Pathophysiology , 2005, Brain pathology.
[114] K. Weinberg,et al. αv‐Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin , 2002, International journal of cancer.
[115] T. Svitkina,et al. Myosin II filament assemblies in the active lamella of fibroblasts: their morphogenesis and role in the formation of actin filament bundles , 1995, The Journal of cell biology.
[116] Koji Yoshimoto,et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. , 2006, Cancer research.
[117] M. Mareel,et al. The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness , 2001, The Journal of cell biology.
[118] S. Aizawa,et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice , 1995, Nature.
[119] T. Lafortune,et al. Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma , 2009, Molecular Cancer Therapeutics.
[120] S. Akiyama,et al. A Novel Protease-docking Function of Integrin at Invadopodia* , 1999, The Journal of Biological Chemistry.
[121] Santosh Kesari,et al. Malignant gliomas in adults. , 2008, The New England journal of medicine.
[122] J. Hickman,et al. Blockade of αvβ3 and αvβ5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells , 2006 .
[123] R. Pazdur,et al. Food and Drug Administration Drug Approval Summary: Temozolomide Plus Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme , 2005, Clinical Cancer Research.
[124] H. Kessler,et al. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. , 2006, Current pharmaceutical design.
[125] D. Moreau,et al. Original triazine inductor of new specific molecular targets, with antitumor activity against nonsmall cell lung cancer , 2008, International journal of cancer.
[126] Richard LeBlanc,et al. Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes. , 2002, Cancer research.
[127] D. Osoba,et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.
[128] S. Blystone,et al. Purified Integrin Adhesion Complexes Exhibit Actin-Polymerization Activity , 2006, Current Biology.
[129] J. Saras,et al. Rho GTPases have diverse effects on the organization of the actin filament system. , 2004, The Biochemical journal.
[130] M. Wolfe,et al. Selective amyloid-β lowering agents , 2008, BMC Neuroscience.
[131] P. D’Eustachio,et al. Cellular functions of TC10, a Rho family GTPase: regulation of morphology, signal transduction and cell growth , 1999, Oncogene.
[132] D. Louis,et al. The retinoblastoma gene is involved in malignant progression of astrocytomas , 1994, Annals of neurology.
[133] R. Klemke,et al. Regulation of Cell Contraction and Membrane Ruffling by Distinct Signals in Migratory Cells , 1999, The Journal of cell biology.
[134] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[135] J. Thiery,et al. Reversible transition towards a fibroblastic phenotype in a rat carcinoma cell line , 1989, International journal of cancer. Supplement = Journal international du cancer. Supplement.
[136] S. Almo,et al. Cellular localization of activated N-WASP using a conformation-sensitive antibody. , 2004, Cell motility and the cytoskeleton.
[137] C. Marosi,et al. Survival and prognostic factors of patients with unresectable glioblastoma multiforme , 2003, Anti-cancer drugs.
[138] J. Condeelis,et al. Cofilin takes the lead , 2005, Journal of Cell Science.
[139] Anne J. Ridley,et al. The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors , 1992, Cell.
[140] M. Westphal,et al. Migration of human glioma cells on myelin. , 1996, Neurosurgery.
[141] G. O'Neill,et al. The coordination between actin filaments and adhesion in mesenchymal migration , 2009, Cell adhesion & migration.
[142] L. Chin,et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. , 2007, Genes & development.
[143] J. Heino,et al. Evolution of collagen-based adhesion systems. , 2009, The international journal of biochemistry & cell biology.
[144] Z. Kam,et al. Early molecular events in the assembly of matrix adhesions at the leading edge of migrating cells , 2003, Journal of Cell Science.
[145] S. Hanks,et al. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases , 1995, Molecular and cellular biology.
[146] C. James,et al. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.
[147] H. Wheeler,et al. Loss of prostaglandin D2 synthase: a key molecular event in the transition of a low-grade astrocytoma to an anaplastic astrocytoma , 2008, Molecular Cancer Therapeutics.
[148] J W Smith,et al. Integrin activation controls metastasis in human breast cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[149] E. Adamson,et al. Rescue of the mutant phenotype by reexpression of full-length vinculin in null F9 cells; effects on cell locomotion by domain deleted vinculin. , 1998, Journal of cell science.
[150] C. Lipinski,et al. Extended survival of Pyk2 or FAK deficient orthotopic glioma xenografts , 2008, Journal of Neuro-Oncology.
[151] E. Tracey,et al. Cancer in New South Wales Incidence and Mortality 2000 featuring projections of selected sites to 2010 , 2002 .
[152] Lucienne Juillerat-Jeanneret,et al. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles? , 2008, Drug discovery today.
[153] Jill M. Stukel,et al. Targeted drug delivery for treatment and imaging of glioblastoma multiforme , 2009, Expert opinion on drug delivery.
[154] E. Ruoslahti,et al. Control of adhesion-dependent cell survival by focal adhesion kinase , 1996, The Journal of cell biology.
[155] I. Pollack,et al. Expression of p53 and prognosis in children with malignant gliomas. , 2002, The New England journal of medicine.
[156] Daniel L. Gustafson,et al. Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors , 2007 .
[157] K. Burridge,et al. Focal adhesions, contractility, and signaling. , 1996, Annual review of cell and developmental biology.
[158] C. Damsky,et al. FAK integrates growth-factor and integrin signals to promote cell migration , 2000, Nature Cell Biology.
[159] M. Westphal,et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. , 2001, Cancer research.
[160] R. Stupp,et al. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. , 2009, Neuro-oncology.
[161] Kathleen R. Lamborn,et al. Cilengitide Targeting of αvβ3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts , 2002 .
[162] R. Milo,et al. A paxillin tyrosine phosphorylation switch regulates the assembly and form of cell-matrix adhesions , 2006, Journal of Cell Science.
[163] C. Tepper,et al. The Src Inhibitor AZD0530 Blocks Invasion and May Act as a Radiosensitizer in Lung Cancer Cells , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[164] H. Wheeler,et al. Variation of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma , 2008, Journal of Neuro-Oncology.
[165] R. Ezzell,et al. Targeted disruption of vinculin genes in F9 and embryonic stem cells changes cell morphology, adhesion, and locomotion. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[166] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[167] D. Yamazaki,et al. Involvement of Rac and Rho signaling in cancer cell motility in 3D substrates. , 2009, Oncogene.
[168] David S. Miller,et al. Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System Pharmacotherapy , 2008, Pharmacological Reviews.
[169] C. Der,et al. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K , 1997, Nature.
[170] W. Cavenee,et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[171] Timothy Y. Huang,et al. Cofilin phosphatases and regulation of actin dynamics. , 2006, Current opinion in cell biology.
[172] T. Byzova,et al. Mechanisms of Integrin–Vascular Endothelial Growth Factor Receptor Cross-Activation in Angiogenesis , 2007, Circulation research.
[173] O. Destaing,et al. Actin machinery and mechanosensitivity in invadopodia, podosomes and focal adhesions , 2009, Journal of Cell Science.
[174] G. Reifenberger,et al. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. , 1994, Cancer research.
[175] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[176] Y. Yonekawa,et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[177] Hong Wu,et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[178] L. Cramer. Organization and polarity of actin filament networks in cells: implications for the mechanism of myosin-based cell motility. , 1999, Biochemical Society symposium.
[179] P. Kleihues,et al. Genetic pathways to primary and secondary glioblastoma. , 2007, The American journal of pathology.
[180] Douglas C. Miller,et al. Preferential Inactivation of the p53 Tumor Suppressor Pathway and Lack of EGFR Amplification Distinguish de novo High Grade Pediatric Astrocytomas from de novo Adult Astrocytomas , 2000, Brain pathology.
[181] V. Golubovskaya,et al. TAE226 Inhibits Human Neuroblastoma Cell Survival , 2008, Cancer investigation.
[182] W. Paulus,et al. Diffuse brain invasion of glioma cells requires beta 1 integrins. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[183] P. Black,et al. αvβ3 and αvβ5 Integrin Expression in Glioma Periphery , 2001 .
[184] K. Rottner,et al. Live imaging of glioblastoma cells in brain tissue shows requirement of actin bundles for migration. , 2006, Neuron glia biology.
[185] M. Vogelbaum,et al. Novel drug delivery strategies in neuro-oncology , 2009, Neurotherapeutics.
[186] J. Guan,et al. Stimulation of cell migration by overexpression of focal adhesion kinase and its association with Src and Fyn. , 1996, Journal of cell science.
[187] M. Martel,et al. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. , 1999, International journal of radiation oncology, biology, physics.
[188] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[189] J. Taylor,et al. An SH3 domain-containing GTPase-activating protein for Rho and Cdc42 associates with focal adhesion kinase , 1996, Molecular and cellular biology.
[190] G. O'Neill,et al. Tropomyosins as interpreters of the signalling environment to regulate the local cytoskeleton. , 2008, Seminars in cancer biology.
[191] B. Felding-Habermann,et al. Integrin adhesion receptors in tumor metastasis , 2004, Clinical & Experimental Metastasis.
[192] G. Borisy,et al. Cell Migration: Integrating Signals from Front to Back , 2003, Science.
[193] Kenneth M. Yamada,et al. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. , 1998, Science.
[194] D. Webb,et al. Differential Dynamics of α5 Integrin, Paxillin, and α-Actinin during Formation and Disassembly of Adhesions in Migrating Cells , 2001, The Journal of cell biology.
[195] C. Gladson. Expression of Integrin avß3 in Small Blood Vessels of Glioblastoma Tumors , 1996 .
[196] Daniel J Brat,et al. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. , 2004, The international journal of biochemistry & cell biology.
[197] J. Houghton,et al. Tumor microenvironment: The role of the tumor stroma in cancer , 2007, Journal of cellular biochemistry.
[198] S. Hanks,et al. Mechanisms of CAS Substrate Domain Tyrosine Phosphorylation by FAK and Src , 2001, Molecular and Cellular Biology.
[199] W. K. Alfred Yung,et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.
[200] J. S. Rao,et al. Molecular mechanisms of glioma invasiveness: the role of proteases , 2003, Nature Reviews Cancer.
[201] D. Hallahan,et al. SRC family kinase inhibitor SU6656 enhances antiangiogenic effect of irradiation. , 2006, International journal of radiation oncology, biology, physics.
[202] R. Klemke,et al. Purification of pseudopodia from polarized cells reveals redistribution and activation of Rac through assembly of a CAS/Crk scaffold , 2002, The Journal of cell biology.
[203] R. DePinho,et al. Malignant glioma: genetics and biology of a grave matter. , 2001, Genes & development.
[204] A. Unterberg,et al. Uniform MDM2 overexpression in a panel of glioblastoma multiforme cell lines with divergent EGFR and p53 expression status. , 2006, Anticancer research.
[205] T. Mikkelsen,et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[206] C. Nobes,et al. Rho, Rac, and Cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia , 1995, Cell.
[207] K. Pienta,et al. Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview , 2000, Prostate Cancer and Prostatic Diseases.
[208] David A. Cheresh,et al. Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.
[209] R. Stupp,et al. Integrin inhibitors reaching the clinic. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[210] H. Vogel,et al. αvβ3 Integrin in central nervous system tumors , 2005 .
[211] J. Guan,et al. Phosphorylation of Tyrosine 397 in Focal Adhesion Kinase Is Required for Binding Phosphatidylinositol 3-Kinase* , 1996, The Journal of Biological Chemistry.
[212] S. Hanks,et al. Identification of p130Cas as a Mediator of Focal Adhesion Kinase–promoted Cell Migration , 1998, The Journal of cell biology.
[213] N. Carragher,et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 , 2009, Molecular oncology.
[214] K. Hahn,et al. Localized Rac activation dynamics visualized in living cells. , 2000, Science.
[215] L. Grochow,et al. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[216] T. Hunter,et al. Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase , 1994, Nature.
[217] J. Bruce,et al. Somatic mutations of PTEN in glioblastoma multiforme. , 1997, Cancer research.
[218] S. Horvath,et al. Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.
[219] Peter Friedl,et al. Cell migration strategies in 3‐D extracellular matrix: Differences in morphology, cell matrix interactions, and integrin function , 1998, Microscopy research and technique.
[220] G. O'Neill,et al. Tropomyosin Isoform Expression Regulates the Transition of Adhesions To Determine Cell Speed and Direction , 2009, Molecular and Cellular Biology.
[221] E Biganzoli,et al. Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[222] Y. Yonekawa,et al. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C --> A:T mutations of the TP53 tumor suppressor gene. , 2001, Carcinogenesis.
[223] H. Mellor,et al. The novel Rho-family GTPase Rif regulates coordinated actin-based membrane rearrangements , 2000, Current Biology.
[224] J. Norman,et al. αvβ3 and α5β1 integrin recycling pathways dictate downstream Rho kinase signaling to regulate persistent cell migration , 2007, The Journal of cell biology.
[225] R. Hynes. A reevaluation of integrins as regulators of angiogenesis , 2002, Nature Medicine.
[226] Andrew D Norden,et al. Therapeutic strategies for inhibiting invasion in glioblastoma , 2009, Expert review of neurotherapeutics.
[227] H. Kessler,et al. Ligands for Mapping a v 3 -Integrin Expression in Vivo , 2009 .
[228] Giuseppe Trapani,et al. New strategies to deliver anticancer drugs to brain tumors , 2009, Expert opinion on drug delivery.
[229] David A. Cheresh,et al. Role of integrins in cell invasion and migration , 2002, Nature Reviews Cancer.
[230] J. Debus,et al. Inhibition of αvβ3 Integrin Survival Signaling Enhances Antiangiogenic and Antitumor Effects of Radiotherapy , 2005, Clinical Cancer Research.
[231] V. Brunton,et al. Src and focal adhesion kinase as therapeutic targets in cancer. , 2008, Current opinion in pharmacology.
[232] B. Scheithauer,et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[233] Charlie Teo,et al. IQGAP1 and IGFBP2: Valuable Biomarkers for Determining Prognosis in Glioma Patients , 2007, Journal of neuropathology and experimental neurology.
[234] M. Kirschner,et al. The Interaction between N-WASP and the Arp2/3 Complex Links Cdc42-Dependent Signals to Actin Assembly , 1999, Cell.
[235] W. Brück,et al. Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas , 2004, Acta Neuropathologica.
[236] W. Song,et al. v-Crk regulates membrane dynamics and Rac activation , 2008, Cell adhesion & migration.
[237] P. Keng,et al. Inhibition of invasiveness of human lung cancer cell line H1299 by over‐expression of cofilin , 2005, Cell biology international.
[238] J. Stull,et al. Dedicated Myosin Light Chain Kinases with Diverse Cellular Functions* , 2001, The Journal of Biological Chemistry.
[239] C. James,et al. Clonal genomic alterations in glioma malignancy stages. , 1988, Cancer research.
[240] C. Sawyers,et al. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.
[241] K. Kaibuchi,et al. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. , 2001, Trends in pharmacological sciences.
[242] Michael D Schaller,et al. The interplay between Src and integrins in normal and tumor biology , 2004, Oncogene.